Ziconotide Evidence Guide
Ziconotide (Prialt) is FDA-approved for severe chronic pain via intrathecal delivery - the only non-opioid intrathecal analgesic with regulatory approval. Phase 3 data demonstrates significant pain reduction in patients refractory to other analgesics including intrathecal opioids. Its N-type calcium channel mechanism is fully differentiated from opioid pathways. A highly specialized but validated analgesic for refractory chronic pain.
Our Take
Ziconotide (Prialt) is FDA-approved for severe chronic pain via intrathecal delivery - the only non-opioid intrathecal analgesic with regulatory approval. Phase 3 data demonstrates significant pain reduction in patients refractory to other analgesics including intrathecal opioids. Its N-type calcium channel mechanism is fully differentiated from opioid pathways. A highly specialized but validated analgesic for refractory chronic pain.
- Evidence context
- Severe chronic refractory pain (intrathecal), N-type calcium channel pharmacology, non-opioid analgesic research
- Evidence grade
- Level A
- Confidence
- High
- Reference context
- Regulatory label reference: 0.1mcg/hour intrathecal (starting dose, titrated slowly to max 19.2mcg/day) - requires intrathecal pump
Benefits and Evidence
- Severe Chronic Pain Relief: Level A, includes human evidence - Phase 3 trials demonstrated significant pain reduction (VASPI scores) in patients with severe chronic pain refractory to other therapies, including those with cancer and non-cancer pain.
- Opioid-Sparing Effect: Level B, includes human evidence - Allows reduction or elimination of intrathecal opioids in some patients, reducing opioid-related side effects while maintaining analgesia.
- Neuropsychiatric Side Effects: Level A, includes human evidence - Cognitive impairment, hallucinations, and psychiatric symptoms are significant dose-limiting adverse effects requiring careful dose titration.
Side Effects and Warnings
- Dizziness
- Nausea
- Confusion and cognitive impairment
- Nystagmus
- Hallucinations
- Gait disturbance
- Urinary retention
- Severe psychiatric symptoms (psychosis, suicidal ideation) - discontinue if these occur
Research Dosage References
- <strong>Intrathecal infusion</strong> - 0.1-19.2 mcg/day - Continuous via implanted pump - Start at 2.4 mcg/day or less. Titrate slowly - no more than 2.4 mcg/day increase, no more than 2-3 times per week. Maximum recommended: 19.2 mcg/day.
Mechanism of Action
Ziconotide provides analgesia through selective calcium channel blockade: 1. N-type calcium channel (Cav2.2) blockade: Selectively and reversibly blocks pre-synaptic N-type voltage-gated calcium channels in the dorsal horn of the spinal cord. 2. Neurotransmitter release inhibition: Prevents calcium influx required for vesicle fusion and release of pain-transmitting neurotransmitters (substance P, glutamate, CGRP) from primary afferent nociceptive neurons. 3. Non-opioid mechanism: Acts independently of opioid receptors, making it effective in opioid-tolerant patients and carrying no risk of respiratory depression or addiction.
Legal Status
FDA-approved (2004) for management of severe chronic pain in patients intolerant of or refractory to other therapies. Schedule V controlled substance. Marketed as Prialt by Jazz Pharmaceuticals.
Primary Sources
- Intrathecal ziconotide in the treatment of refractory pain. JAMA, 2004.
- A randomized, double-blind, placebo-controlled trial of ziconotide for chronic pain. Pain, 2006.
- Ziconotide: a review of its pharmacology and use in chronic pain. Neurotherapeutics, 2007.
Quick Answers
Where is the strongest evidence for Ziconotide?
Ziconotide (Prialt) is FDA-approved for severe chronic pain via intrathecal delivery - the only non-opioid intrathecal analgesic with regulatory approval. Phase 3 data demonstrates significant pain reduction in patients refractory to other analgesics including intrathecal opioids. Its N-type calcium channel mechanism is fully differentiated from opioid pathways. A highly specialized but validated analgesic for refractory chronic pain. Evidence context: Severe chronic refractory pain (intrathecal), N-type calcium channel pharmacology, non-opioid analgesic research.
What are the main side effects of Ziconotide?
Ziconotide side effects and warning signals include Dizziness, Nausea, Confusion and cognitive impairment, Nystagmus, and Hallucinations.
What evidence level is Ziconotide?
Ziconotide is rated Level A; the listed research status is FDA Approved.